Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of M108 plus CAPOX versus placebo plus CAPOX in CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma
CTR20233813Phase 3Active
- Sponsor
- Mingji Biopharmaceutical
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of M108 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Mingji Biopharmaceutical. Started Jan 2024; status: active.
02
Drugs
M108
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20233813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233813.